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Abstract: Cardiovascular diseases (CVD) remain a major cause of death and morbidity globally
and diet plays a crucial role in the disease prevention and pathology. The negative perception
of dairy fats stems from the effort to reduce dietary saturated fatty acid (SFA) intake due to their
association with increased cholesterol levels upon consumption and the increased risk of CVD
development. Institutions that set dietary guidelines have approached dairy products with negative
bias and used poor scientific data in the past. As a result, the consumption of dairy products was
considered detrimental to our cardiovascular health. In western societies, dietary trends indicate
that generally there is a reduction of full-fat dairy product consumption and increased low-fat dairy
consumption. However, recent research and meta-analyses have demonstrated the benefits of full-fat
dairy consumption, based on higher bioavailability of high-value nutrients and anti-inflammatory
properties. In this review, the relationship between dairy consumption, cardiometabolic risk factors
and the incidence of cardiovascular diseases are discussed. Functional dairy foods and the health
implications of dairy alternatives are also considered. In general, evidence suggests that milk has a
neutral effect on cardiovascular outcomes but fermented dairy products, such as yoghurt, kefir and
cheese may have a positive or neutral effect. Particular focus is placed on the effects of the lipid
content on cardiovascular health.
Keywords: milk; cheese; yoghurt; kefir; cardiovascular diseases; inflammation; saturated fatty acids;
atherosclerosis; cardiometabolic risk factors
1. Introduction
Despite advances in improved primary prevention and medical treatment, cardiovascular diseases
(CVD) are the leading cause of death and morbidity in Europe [1] and worldwide [2]. Every year CVD
are responsible for 10,000 deaths in Ireland and 1.8 million in the European Union, due to coronary
heart disease (CHD), stroke and related circulatory diseases [1,3]. Increasing evidence supports the
pivotal function of nutrition in the development of chronic diseases, especially CVD [4]. Maladaptive
diet and lifestyle are the dominant underlying cause of systemic inflammation, which is the core
process that drives the development of atherosclerosis [4,5]. Diet and lifestyle are key modifiable risk
factors for the prevention of CVD and thus have been the focus of intense research. Globally, striking
differences in dietary habits and the rates of chronic disease exist. The identification and subsequent
targeting of dietary factors with the greatest potential for reducing CVD, diabetes and obesity are of
crucial scientific and public health importance [6].
Milk and dairy products are an important nutrient dense constituent of a healthy diet due to
their capacity to provide essential vitamins, minerals, macronutrients and micronutrients important
for growth, development and tissue maintenance. This is vital as globally 6 billion people consume
milk and dairy products, the majority of them in developing countries [7]. Currently there are
Foods 2018, 7, 29; doi:10.3390/foods7030029 www.mdpi.com/journal/foods
Foods 2018, 7, 29 2 of 34
milks of varying fat content and milks with varying vitamin and mineral content (often fortified or
enriched); there are also concentrated milks, high-protein milks, fermented milks and various other
dairy products, including yoghurts and cheeses consumed worldwide. Dairy products are associated
with many negative health effects due to previous observations relating to their saturated fatty acid
(SFA) content, which may lead to increased low-density lipoprotein cholesterol (LDL) levels, thus
an increased risk of cardiovascular disease [8]. There was also a strong correlation evident between
dairy fat consumption and coronary heart disease in an early study [9]. However, recent findings
have indicated that the link between SFA and CVD may be less clear than previously assumed. Foods
are composed of an array of saturated and unsaturated fatty acids, each of which may differentially
affect lipoprotein metabolism, as well as contribute significant quantities of other nutrients that may
alter CVD risk [4,10]; these include phospholipids, milk proteins, calcium and vitamin D, which
have been reviewed in recent literature [4,11]. In addition, recent research trends indicate that dairy
products have a neutral [12–14] or even a positive effect on cardiovascular health [14–19] contrary
to previous assumptions [4]. Dairy products have also been associated with positive health benefits
against diabetes [20], obesity [21–23] and metabolic syndrome [23,24]. The way consumers obtain
nutrition and dietary information has substantially changed. There is conflicting advice online with
regards to every food type and many consumers are more confused now than ever [25]. Discrepancies
in dietary advice due to the increased influence of the food industry, social media and ‘fad diets,’ which
are often endorsed by celebrities and ‘diet gurus’ [26], among other modern phenomena has damaged
consumer confidence in the nutritional value of dairy products. This review aims to assess the effect of
dairy products on cardiometabolic health.
2. Dietary Guidelines and Dairy Product Consumption
Dairy intake is increasing worldwide, yet theoretically dairy products could both increase
and decrease cardiometabolic risk factors. Dairy products have been associated with several
cardiometabolic benefits, however the active constituents have not yet been established. Initially,
dietary guidelines formulated in the 1980s, demonised dairy products due to their high SFA, cholesterol
and calorie content [4]. The rise of the lipid hypothesis led most scientific organisations and
dietary guidelines to recommend low-fat (1%) or non-fat dairy consumption, as a result of their
characteristically high SFA content [27,28]. Now most countries recommend the consumption of
dairy products and when amounts are specified, recommendations are typically for 2 or 3 servings
per day [29]. Although often, as occurs in the UK, general recommendations are made with no
specific amount mentioned [29]. There remains inconsistent health advice to consumers with many
authorities recommending three to four servings a day [27] and labelling dairy as a ‘superfood’ [30].
On the other hand, some dietary guidelines recommend the complete avoidance of full-fat dairy
products [31], others recommend that the consumption of dairy products be limited as much as
possible [32]. However, as research advances, some countries such as Australia have revised their
dietary guidelines and included dairy products but preferably consumption of low-fat as opposed
to full-fat products is advised [33]. Notably, butter and cream do not fall into the category of dairy
products in some dietary recommendations due to their significant contribution of fat to the diet [34].
Nevertheless, dairy products are nutrient dense, providing a wide range of crucial vitamins (A, B6,
B12, D and K), minerals (calcium, iodine, magnesium, potassium, phosphorus and zinc), fats, proteins
and other microconstituents [35,36], which are otherwise difficult to obtain in diets with limited use of
dairy products [29]. In particular, dairy products can provide up to 60% of the recommended daily
allowance (RDA) of calcium [37]. Furthermore, fermented dairy products are an excellent source of
vitamin K, a fat-soluble vitamin [36] that will be discussed further in Section 4.
In addition, fermented dairy products, such as yoghurt have a positive effect on intestinal
microbiota. Therefore, dairy products generally form an integral role in the dietary guidelines of many
countries. However, not all dairy products are created nutritionally equal. For instance, cheeses are
often salted, which contributes to high sodium intake. Soft cheeses typically contain less calcium as
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the curd is formed with acid, some calcium is lost to the whey. The fat content of dairy products can
vary greatly, because of the type of milk, degree of fat removal, the animals condition, diet and the
milk processing [4,29]. Often ice-cream and similar dessert products are included as dairy products
in dietary guidelines. The nutritional quality of these products is diluted by the addition of sugar
and fats [29], in particular high amounts of vegetable fats like coconut oil and palm oil, that have
questionable positive and negative effects on cardiovascular health due to their high lauric acid and
palmitic acid content respectively [38–40]. Therefore, ice cream and dairy desserts that contain high
levels of vegetable oils should be approached with caution and not considered in dairy research or as
part of dairy products in dietary guidelines.
3. Saturated Fat, Cholesterol and Dairy Products
SFA and cholesterol have formed the basis of the ‘lipid hypothesis’ for CVD development.
Consumption of full-fat dairy products was reduced and either substituted by a reduced fat version
or intake was restricted based on government dietary guidelines. However, recent perspectives have
determined more complex mechanisms for the underlying causes, initiation and development of CVD,
that do not necessarily indicate that SFA or cholesterol levels are culpable. This section discusses the
role of SFA and cholesterol on cardiovascular health, with respect to dairy products.
3.1. Saturated Fat
Cholesterol levels are considered the most important risk factor for CVD development and so
milk and dairy products theoretically have detrimental effects on cholesterol concentrations due to
their SFA content [41]. For decades, it has been assumed that SFA (containing 12–18 carbon atoms)
consumption undermines cardiovascular health [42–45]. By the 1960s, the ideologies of the lipid
hypothesis were gathering momentum and the low-fat diet began to be touted for high-risk heart
patients and for people’s health in general. Dietary advice to limit the consumption of SFA appeared
as early as 1961 [46] and the rationale supporting these views was that SFA increased cholesterol
levels, which in turn increases the risk of CVD development [47]. However, by the 1980s, the low-fat
dietary approach became more popular and was promoted by the food industry, medical doctors,
governments and popular health media [48]. Dairy products are high in SFA and their consumption has
long been thought to contribute to CVD development [4]. As dairy products are the only food group
composed of more saturated than unsaturated fat, it became apparent that they may be detrimental
to cardiovascular health. Thus, it was proposed that low-fat or non-fat dairy products be advised to
reduce the risk of developing CVD. However, the extent and precise nature of the role of saturated
fat in CVD development and progression are being re-examined [43,49]. In fact, it has been proposed
by many, that SFA should no longer be considered a single nutrient group but instead should be
considered as individual molecules with specific functions of their own [4,50]. In animal fats, SFA
are generally located in the sn-2 position of the glycerol backbone, while monounsaturated fatty
acids and polyunsaturated fatty acids generally occupy the sn-1 and sn-3 positions, which induce
specific effects on lipoprotein metabolism and atherogenesis [51]. When SFA is reduced in the diet, it is
replaced by another macronutrient such as carbohydrate or protein. These diets do not necessarily
demonstrate a decreased risk of CVD. Generally it is accepted that the replacement of saturated fat by
polyunsaturated fatty acids (PUFA) in the diet is associated with a reduced risk of CVD [52], however
this is still disputed by some due to insufficient evidence [53,54], which has been highlighted in recent
reviews [53,55]. While the substitution of SFA with monounsaturated fatty acids or high-glycaemic
index food remains less clear [52,56].
The proportion of SFA entering the food chain from milk and dairy products is controlled by
industrial skimming, which reduces total milk fat. Other methods to reduce SFA include the alteration
of the animal’s diet to include additional PUFA and monounsaturated fatty acids (MUFA), which
replaces the SFA in the milk [4,57]. Initiatives include the supplementation of the bovine diet with an
oleic acid-rich diet, through the addition of marine oils, plant oil and oilseeds as a novel means to
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reduce the intake of SFA [58]. In a recent study plant oils were supplemented to a grass silage-based
bovine diet, which managed to reduce ruminal CH4 emission and milk saturated fatty acids but
also increased the proportion of unsaturated fatty acids and total conjugated linoleic acid within the
milk [59], thus possibly creating a feed that sustainably improves the lipid profile of the milk. Dairy
products contain short, medium and long-chain SFA, which affect cardiovascular health differently.
It is apparent that lauric (12:0), myristic (14:0) and palmitic (16:0) have adverse effects on LDL, which
is considered an important risk factor for CVD [60]. When compared to carbohydrate consumption in
humans, lauric acid, myristic acid and palmitic acid raised total cholesterol and LDL, whereas stearic
acid (18:0) does not. SFA raises high-density lipoproteins (HDL) but these effects are greater as the fatty
acid chain length decreases and so generally lauric acid has the most beneficial effect on cholesterol
profile [61]. Based on these studies, lauric acid may be a heart-healthy SFA [56].
The effectiveness of the reduction of SFA in the diet to lower CVD development has been the
subject of major controversy and debate that reignites regularly [56]. The weaknesses in the data [62,63],
the complex disease pathology, the numerous risk factors and the inadequate reliance on single
biomarkers to assess CVD risk [52,56] have highlighted a number of discrepancies in the ‘lipid
hypothesis’. Several meta-analyses and systematic reviews further cast doubt over the effect of SFA on
CVD outcomes [49,64], particularly the controversial PURE study, which assessed the dietary intake of
135,335 subjects from 18 countries across five continents for 7.4 year and found that total fat and types
of fat were not associated with CVD, myocardial infarction, or CVD mortality. Further still, SFA was
inversely associated with stroke [65]. The PURE study investigators state that advice to restrict SFA
“is largely based on selective emphasis on some observational and clinical data, despite the existence
of several randomised trials and observational studies that do not support these conclusions” [65].
3.2. Dietary Cholesterol
Dairy products contain approximately 80 mg/110 g dietary cholesterol. However, the previous
notion that dietary cholesterol may increase the risk of developing CVD is currently under debate,
since it is not well-supported in the literature. It is thought that the lack of evidence may depend on an
individual predisposition to synthesise versus absorb cholesterol [66,67]. Therefore, dietary guidelines
in the US [68], which recommended that cholesterol consumption be kept below 300 mg/day have
come into question [66]. These recommendations were based on poor scientific evidence, apart from a
known association between saturated fat and cholesterol and specific animal studies where cholesterol
was fed in amounts far exceeding normal intakes [66]. In contrast, Canada [69], Ireland [28], the UK [70],
Korea [71], New Zealand [72] and other Asian and European countries do not prescribe an upper limit
for dietary cholesterol [66]. Epidemiological studies have shown that increasing dietary cholesterol
levels are not correlated with increased risk of CVD [73–75]. However, clinical studies demonstrate
that dietary cholesterol may increase serum LDL in certain individuals (hyper-responders); this is
generally accompanied by increases in HDL. Therefore, the LDL/HDL ratio in hyper-responders
remains the same [76,77]. The size of circulating LDL particles is also a major risk factor for CVD,
which dietary cholesterol has the ability to reduce [66]. Controversy also surrounds the consumption
of eggs due to their high cholesterol content, even though egg intake is associated with a number of
benefits against CVD [53,78]. However it was researchers in this field that highlighted the need to
review dietary cholesterol recommendations [66].
The effect of dairy consumption on cholesterolaemia has exhibited varied results. An early study
demonstrated that high milk intake in an African Maasai ethnic group was inversely correlated with
blood cholesterol levels [79]. Later, these observations were confirmed by others [80–82] and it was
hypothesised that that this effect was a result of intestinal microbial fermentation of indigestible
carbohydrates, that could alter cholesterol synthesis and disrupt enterohepatic circulation, thus
lowering cholesterolaemia [83]. Studies eventually expanded to various dairy products; one examined
the effects of an isoenergetic (20% of total calories, normalised for casein and lactose) provision of milk
(2164 mL), butter (93 g) and cheese (305 g) administered in three sessions over three weeks. The authors
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found that cheese did not significantly raise LDL levels. In contrast, whole milk raised serum LDL
levels similarly to butter [84]; results that were subsequently confirmed by Biong et al. who also
demonstrated that consumption of cheese induced a lower increase of serum LDL cholesterol levels in
22 participants, in contrast to an identical mass of butter (42 g) consumed [85]. It was hypothesised that
the different effects were a result of different calcium contents between the dairy products. Another
study fed 40 g/day of either butter or mature cheddar cheese to 19 mildly hypercholesterolaemic
participants four weeks in a randomised crossover trial [86]. They observed that total cholesterol and
LDL cholesterol increased significantly in the butter group (p < 0.05) versus cheese, which has been
observed previously [86]. The authors suggested that dietary advice surrounding cheese consumption
should be revised. This was also questioned by Tholstrup et al. who suggested that modest amounts
of cheese should be included in the diets of mildly hypercholesterolaemic participants [84]. Similar
studies have observed similar results for cheese consumption. A recent study replaced 13% of the daily
calorie intake with 47 g of butter or 143 g of cheese that possessed the same lipid content for six weeks
in 49 participants. The results of the randomised crossover trial indicated that compared with the
run-in period, cheese did not increase serum LDL cholesterol levels; rather as compared with butter,
cheese induced a significantly lower increase in total (5.7%) and LDL (6.9%) cholesterol [87]. However,
there was a lack of difference reported in the cholesterolaemic effects on diets containing full-fat milk
and butter [41]. These observations have been observed in a recent study that compared the effect
of equal amounts of SFA from butter and cheese intake in 92 overweight subjects [88]. Their results
also indicated that consumption of SFA from butter and cheese had similar effects on HDL levels but
differential effects on LDL levels, which they suggest may be explained by the food-matrix effect.
Several attempts have been made to elucidate the mechanisms surrounding the differential effects
of cheese and butter on cholesterolaemia. One theory is that calcium intake may increase faecal
excretion of bile acids that would cause a regeneration of bile acids from hepatic cholesterol and
thereby result in a lowering of plasma cholesterol concentrations. It is thought that the higher calcium
concentration in cheese combines with fatty acids in the intestine and forms insoluble detergents.
In addition, hydrophobic aggregates can form between phosphorus and bile acids that can be excreted
and measured; these observations are indicative of reduced fat absorption [89,90]. Higher-fat faecal
excretion has been observed in cheese groups versus butter groups [87]. However, a randomised
controlled crossover dietary intervention study assessing bile acid and calcium concentrations in faecal
samples from humans after intake of cheese and butter in 23 participants, again replacing 13% of
their of their daily calorie intake was conducted to confirm these observations [91]. After 6 weeks
of the intervention, cheese resulted in higher amounts of calcium excreted in faeces compared to
butter. However, no difference was observed in faecal bile acid output despite lower serum total,
LDL and HDL cholesterol concentrations observed with cheese intake. Although well designed, it is
unfortunate that the mechanisms responsible for the lowering of cholesterol concentrations with cheese
compared to butter intake remain unresolved. It is also thought that the protein and probiotic content
of cheese may contribute to the observed neutral effect on serum cholesterol [91]. In addition, butter is
not necessarily a good comparator for studies examining cheese intake [34]. Also, there are several
confounding variables that prevent the formation of any solid conclusions in relation to cheese and
CVD risk due to the differential effect of individual cheese varieties that differ in macronutrient content,
degree of fermentation and food matrix [10].
Butter was previously associated with negative CVD outcomes. However, growing uncertainty
and changing views on the role of butter in CVD has been highlighted by many, particularly Time
Magazine [92]. Butter is composed of mainly milk fat but can contain some proteins, water and
sometimes added salt. Butter fat in general consistently raises plasma cholesterol concentrations, especially
in hypercholesterolaemic individuals and so may pose a risk to cardiovascular health [86,88,93,94].
Butter consumption has been consistently associated with negative cardiovascular risk outcomes due
to the focus on cholesterol levels, however the long-term effects of butter consumption on other major
endpoints, such as all-cause mortality and CVD, are also not well-established. In 2014, a systematic
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review and meta-analysis that examined the effect of butter consumption in 636,151 subjects from
15 country-specific cohorts on the risk of CVD, type II diabetes mellitus (T2DM), and total mortality
was published [95]. Pimpin and colleagues discovered that butter was weakly associated with all-cause
mortality in (N = 9 country-specific cohorts; per 14 g/day: relative risk (RR) = 1.01, 95% confidence
interval (CI) = 1.00–1.03, p = 0.045); was not significantly associated with any CVD (N = 4; RR = 1.00,
95% CI = 0.98–1.02; p = 0.704), coronary heart disease (N = 3; RR = 0.99, 95% CI = 0.96–1.03; p = 0.537),
or stroke (N = 3; RR = 1.01, 95% CI = 0.98–1.03; p = 0.737) and was inversely associated with incidence
of diabetes (N = 11; RR = 0.96, 95% CI = 0.93–0.99; p = 0.021) [95]. The association of butter and CVD
may not be as clear cut as previously thought. There is a lack of published studies to conclusively label
butter as positive or negative on cardiovascular health. Thus, future studies must examine the effects
of butter consumption on CVD risk, inflammatory markers and other risk factors to put the butter
debate to rest.
3.3. Low-Fat Dairy products
Since the 1970s, dietary guidelines were based on the findings of the ‘Seven Countries Study’,
which indicated that high intakes of SFA and cholesterol were correlated with CVD. In light of these
findings, 1977 saw the first edition of ‘The Dietary Goals for the United States’. These guidelines were
formed in an attempt to reduce the incidence of diet-related diseases such as CVD [96]. The guidelines
specified several alterations that were believed to improve health, including the alteration of fat
consumption for Americans. While these guidelines were well-intended, they promoted the overhaul
of the food industry and the average American’s perception of a nutritious diet, eventually contributing
to overall decline in health, an increased national obesity and CVD rate, rather than the projected
opposite result [97]. Diets from the 1970s onwards began to rely upon highly processed foods,
increased food consumption away from home and a greater use of edible oils and sugar sweetened
beverages, which coincided with reduced physical activity and an increased sedentary lifestyle [97].
The recommendations initiated the production of heavily used vegetable oils, radically altering the
dietary n-6/n-3 ratio and increasing the requirement for hydrogenated oils. The food industry used
excess sugar in product development in order to accommodate for the loss of flavour due to the
reduction of fat in processed products. In addition, the advertising of ‘low-fat’ food labels further
convinced people that ‘low-fat’ was synonymous with ‘healthy’, increasing the intake of overly
processed foods and decreasing health status [97]. In fact, the United States government advised
the public to increase their intake of carbohydrate (6–11 servings) and to consume all fats sparingly,
as illustrated in the food guide pyramid of 1992 [98].
Low-fat dairy products became popular and easy to produce in response to consumer’s needs for
reduced fat in food products. Considerable debate surrounds whether the intake of low-fat or whole fat
dairy products are more beneficial for cardiovascular health. Globally, trends show that full-fat dairy
consumption has fallen since the 1970s and low-fat dairy consumption has increased [88]. However,
studies tend to indicate that whole-fat dairy consumption has a beneficial effect on CVD health and may
be more beneficial than low-fat dairy consumption, particularly in relation to inflammatory markers
(Table 1). However, low-fat dairy products and whole milk have been associated with lower risk of
hypertension in several recent meta-analyses [99–102]. The Dietary Approaches to Stop Hypertension
Trial (DASH) found that low-fat or fat-free dairy foods added significant benefits to vegetables and
fruits in lowering blood pressure [103]. Other studies have found dairy consumption in general to
be associated with lower blood pressure regardless of the fat content, due to the presence of calcium,
vitamin D and other bioactive molecules such as peptides [104,105]. Interestingly, consumption of
full-fat dairy as opposed to low-fat dairy products has been beneficially associated with higher vitamin
D stores and lower body mass index (BMI), especially in young children [106,107].
Researchers from the Observation of Cardiovascular Risk Factors in Luxembourg Survey
analysed 1352 adults over 3 months using a semi quantitative food frequency questionnaire, various
anthropometric and haemorheological values, while accounting for physical activity and smoking
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to develop a cardiovascular health score (CHS) that was determined by summing the total number
of health metrics at ideal levels. Their resulting data indicates that participants that consumed at
least three serving of dairy foods per day had a better CHS than those who consumed less than three
servings a day (p = 0.04). Additionally, higher intake of full-fat dairy was related to a better CHS
(p = 0.06) and depending on the fat content of the dairy products, a higher intake of full-fat dairy
was associated with a better CHS (p = 0.03). Notably, a positive association with total low-fat dairy
product consumption was not observed (p = 0.22). Furthermore, no association between dairy product
consumption and blood pressure, fasting plasma glucose and total cholesterol was observed [22].
However, this study was a cross-sectional study, thus it prevents the establishment of casual inference
regarding dairy food intake on CVD health or risk [22,108].
It has also been suggested that total and especially full-fat dairy food (p < 0.001) intakes are
inversely and independently associated with metabolic syndrome in middle-aged and older adults,
associations that seem to be mediated by dairy SFA [109]. However, a different study has shown that
high intakes of yoghurt and fermented products were cross-sectionally associated with lower odds
of presenting with newly diagnosed T2DM and impaired glucose metabolism by 25–40% relative
to lower intakes. However, associations of total dairy product intake, full-fat products, skimmed
products and Dutch cheese did not reveal similar direction and magnitude for newly diagnosed
T2DM or impaired glucose metabolism [110]. These studies suggest that there is a distinct lack of
evidence to suggest that full-fat dairy products are associated with a higher risk of CVD, which is
in concurrence with several other research groups [10,49,111]. Research also eludes to the fact that
low-fat dairy products and full-fat milk consumption are both associated with a reduced risk of
hypertension [105] and insulin resistance [112]. Furthermore, fermented dairy products may be more
beneficial for cardiovascular health and full-fat dairy consumption in general may have a positive effect
on cardiovascular health. Therefore, it is clear that dietary recommendations to avoid full-fat dairy
intake are not supported by the literature; further research is required to elucidate the cardioprotective
mechanisms of dairy products.
3.4. Limitations to Dairy Research: The Dairy Matrix Effect
Nutritional research traditionally has followed a reductionist, nutrient focused approach that
evaluated the effect of a single nutrient group linking one nutrient to one health effect. This may partly
explain why discrepancies exist in nutritional research [67]. The classic example of this approach is the
link between SFA consumption and CVD. This narrow-minded approach has led to the demonization
of foods high in SFA, that have been labelled ‘bad’ for cardiovascular health. In the case of lipids,
because of the high heterogeneity of structures and functions, scientists are beginning to realise that
different lipids may have differential cardiometabolic effects. There is also increasing evidence that
assessing the ‘food matrix’, rather than just a single nutrient may be a more accurate evaluation of the
effects of dairy foods on health and needs to be taken into account in food research [90]. This topic
has been highlighted and reported by Thorning et al. [113], who concluded that the dairy matrix has
specific beneficial effects on cardiometabolic health, body weight and bone health, observations that
differ to that of single nutrient constituents. The large numbers of different nutrients combined in a
complex physical structure has implications for digestion absorption and metabolism, affecting the
overall nutritional properties of the food [113]. They also concluded that different dairy products
have the potential to exert different and varying health effects and disease risk markers. Overall, the
nutritional value of dairy products should be considered as the biofunctionality of the sum of the
nutrients within the dairy matrix structures. A clear example of the dairy matrix effect can be seen in
the studies examining the differential effects of cheese and butter on serum cholesterol levels. Another
core area of research in lipid studies that needs to be investigated is in estimating frequency, diversity
and rate of lipid modifications. Based on previous studies by mass spectrometry, it has been succinctly
expressed that lipid modifications do alter bio-functionality but its effect on gastrointestinal digestion
has yet to be revealed. Processing treatments induce oxidative and thermal induced modifications
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that may affect lipid nutritional profile, which in turn encourages formation of advanced lipid end
products that accelerate the initiation of CVD. Therefore, sustainable treatment regimens must be
deployed to conserve bioactive lipid content.
4. Dairy Products and Cardiometabolic Health
Metabolic syndrome, T2DM, hypertension and obesity are all conditions interconnected with CVD
due to similarities in their mechanisms, pathology and systemic inflammation. Systemic inflammation
persists in elderly people due to immunosenescence and in those who are obese due to their increased
mass of adipose tissue and resulting increase in adipokines. This significantly increases an individual’s
risk for endothelial dysfunction and CVD development [4,114]. Metabolic syndrome is a cluster of
metabolic risk factors that are associated with increased risk of CVD and T2DM. Metabolic syndrome
is typically classified based on an individual exhibiting abnormalities beyond specific parameters of
blood pressure, fasting glucose, waist circumference, fasting triglycerides and HDL cholesterol, all
of which can worsen with age [115]. Recent research indicates that dairy products may be associated
with several beneficial effects on cardiometabolic outcomes.
4.1. Dairy Products and Hypertension
Hypertension is one of the leading risk factors for the development of stroke and coronary
heart disease. Moreover, novel markers of vascular health include the measuring of arterial stiffness.
The health of the walls of blood vessels is a key determinant in cardiovascular disease. Gradual loss in
elasticity is a major factor in blood pressure and evidence of ‘hardening’ of the artery as a consequence
of atherosclerosis contributes to intra-arterial thrombosis, occlusion and consequent infarction [116].
Arterial stiffness develops with age and can be influenced by diet and lifestyle. Arterial stiffness in
an independent predictor of CVD events and mortality [117,118]. Aortic pulse wave velocity and
augmentation index are used to determine alterations in vascular function, which are predictive of
heart attack and stroke [108,116,118]. Evidence suggests that the intake of milk and dairy products has
a positive impact on hypertension [118]. The DASH study [119] has shown reductions in the diastolic
and systolic pressures of subjects that consumed low-fat dairy products. This has been seen in later
studies that confirmed these relationships by demonstrating a significantly reduced relative risk for
hypertension (RR = 0.97) [101]. Another study found a significant reduction of systolic blood pressure
in overweight individuals who consumed three servings of low-fat dairy products over 8 weeks [120].
A recent study has shown that hypertensive individuals who consumed ≥2 servings per week of
yoghurt were at lower risk of developing CVD [121]. Several aforementioned meta-analyses have
found similar associations with dairy intake and blood pressure [100,101]. A recent meta-analyses
has found that low-fat dairy products may be associated with the reduced risk of hypertension [102].
Furthermore, Gholami et al. found that total dairy intake demonstrated an inverse association with
stroke and CVD [122]. In addition, the Caerphilly Prospective Study demonstrated significant inverse
relationships between dairy intake and augmentation index [118]. Mechanistically it is thought that
bioactive lipids and peptides may play a role in hypertension reduction [4,123,124]. Therefore, further
research is warranted to decipher the mechanisms that govern the observed beneficial health effects of
dairy product consumption on hypertension and the risk of stroke.
4.2. Dairy Products and Diabetes
Excess energy intake is associated with the development of obesity and insulin resistance,
key metabolic features in the pathophysiology of T2DM. Excess intake of dietary nutrients is
an important risk factor for obesity and insulin resistance [125], thus logic would suggest that
dairy products being nutrient dense may increase the risk of T2DM. On the contrary, several
observational studies have concluded that the consumption of dairy foods is associated with improved
insulin resistance [112,126–129]. Furthermore, a recent meta-analysis of randomised controlled
trials concluded that increasing dairy food intakes did not significantly impact cardiometabolic
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risk factors [130]. Four other meta-analyses that combined data from 4–14 studies spanning
167,000–459,790 subjects are consistent in showing no significant association between milk consumption
and the risk of T2DM (RR, ranging from 0.87 to 0.95; 95% CI, ranging from 0.69 to 1.67, depending on
whether or not reduced fat or full-fat milk was considered) [131–134]. A mendelian randomisation
study on a Danish cohort of 97,811 individuals demonstrated that milk consumption as assessed
observationally or genetically via lactase persistence, was not associated with the risk of T2DM [135].
The large EPIC study of 12,403 cases of T2DM in 8 European countries demonstrated no significant
association between total dairy intake and T2DM but combined fermented dairy (cheese, fermented
milk and yoghurts) was associated with protection against T2DM with a 12% reduction (ptrend = 0.02)
when comparing extreme quintiles [136]. Particularly in the Norfolk-EPIC cohort, a 24% reduction of
risk for low-fat fermented products and a 28% reduction for yoghurt intake (both ptrend < 0.05) [137].
Furthermore, in a systematic review of the literature, Morio et al. concluded that there is no evidence
that dietary saturated fatty acids from varied food sources affect the risk of insulin resistance or T2DM,
nor is intake of full-fat dairy products associated with this risk. Moreover, they deduced that the
inverse association between dairy consumption and T2DM may be due to other components within the
dairy matrix. Therefore, future studies on the effects of dietary saturated fatty acids should take into
account the complexity of the food matrix [125]. Mechanistically, it is thought that anti-diabetogenic
properties of dairy may be a result of the presence of bioactive lipids such as rumenic and vaccenic acids
(Conjugated linoleic acids—CLA), butyric acid and the presence of other biologically active molecules
such as phytanic acid, vitamin A and bioactive peptides that may interact with the activation of the
peroxisome proliferator-activated receptor-γ (PPAR-γ) [138]. The totality of the evidence indicates
that dairy consumption, in particular fermented dairy products are associated with a reduced risk
of T2DM.
4.3. Dairy Products and Obesity
Obesity is an important risk factor for the development of CVD and other chronic diseases.
The rate of obesity among children in developed countries such as Ireland and the United States
continues to be a major concern due to the increased risk of CVD and T2DM [139,140]. Dairy foods
characterised by their high SFA content and calorie content, pose a potential risk for weight gain
and obesity. However, research thus far has led to conflicts and contradictions concerning this
notion. Several cross-sectional studies have shown an inverse relationship between body mass index
(BMI) or adiposity and dairy intake in children [139,141,142], however this is not consistent between
studies [143]. Some studies indicate a slight weight gain when eating full-fat dairy products [105].
A systematic review of 10 cohort studies demonstrated an inverse association between yoghurt
consumption and the risk of overweight or obesity but this was not uniformly consistent or statistically
significant [144]. A further study has shown that dairy product consumption associated with reduced
risk of obesity in Korean women but not in men [23]. Although many studies demonstrate an inverse
association between dairy products and the risk of being overweight or developing obesity, further
studies are imperative to fully understand these complex associations and provide accurate dietary
guidelines to consumers for weight management.
5. Anti-Inflammatory Properties of Dairy Products
Low-grade inflammation is the key biological phenomenon underpinning the development and
progression of CVD, metabolic syndrome and T2DM. The initiation and resolution of the inflammatory
response involves the complex and coordinated expression of inflammatory compounds, which induce
a myriad of physiological processes, ranging from local vascular response to systemic responses
affecting the whole organism [53]. During atherosclerosis, circulating inflammatory mediators actively
contribute to vascular and atheromatous change [53,145]. As thoroughly reviewed by Da Silva
and Rudkowska [145], there are multiple studies that have examined the role of dairy components
on various cell lines and found that generally these components have an inverse association with
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inflammation. In particular, long-chain SFA such as palmitic (C16:0) and stearic (C18:0) may exhibit
pro-inflammatory effects. Although these fatty acids are both found in abundance in dairy products,
as evidenced by the lack of association between dairy products and CVD, it is suggested that the
deleterious effects by these SFA in milk is offset by other dairy components [145]. Other SFA such
as lauric acid (C12:0) may have a neutral or anti-inflammatory effects, however further research is
required in humans [145].
Platelet-activating factor (PAF) is a potent pro-inflammatory phospholipid mediator implicated
in the initiation and progression of atherosclerosis [146]. PAF and PAF-like molecules act through
their binding to a unique G-protein coupled seven transmembrane receptors (PAF-receptor), which
subsequently triggers multiple intracellular signalling pathways, depending on the target cell
and PAF levels in the tissue and blood [53,147]. PAF in general plays a central role in various
physiological processes, such as mediation of the normal inflammatory responses, regulation of
blood pressure and regulation of coagulation responses [53]. Potential therapeutic approaches to the
pro-inflammatory actions of PAF focus on the PAF/PAF-receptor interactions, thus inhibiting the
exacerbation of the complex PAF-induced inflammatory response and pathways through competitive
and non-competitive displacement of PAF from the PAF-receptor [53]. A number of PAF inhibitors
and/or antagonists have been identified in the polar lipid fractions of numerous food types,
including dairy products [53]. It seems that bovine, ovine and caprine dairy products possess polar
lipids with potent anti-inflammatory activities as demonstrated in a series of in vitro experiments
on washed rabbit platelets [4,148]. Research has shown that as milk is fermented to yoghurt
and then to cheese, the bioactivity of the PAF inhibitors seems to increase [4]. This indicates
that the processes of fermentation and lipolysis play a key role in altering the bioactivity of the
polar lipid fractions of milk and this bioactivity increases the further fermentation proceeds [4,53].
These effects have been attributed to microorganisms such as Lactobacillus delbrueckii ssp. bulgaricus
and Streptococcus thermophilus. Research also indicates that polar lipids of caprine and ovine milk and
dairy products possess greater bioactivity than those of bovine milk and dairy products [148–152].
Many reviews have highlighted that dairy products are associated with positive effects on
cardiovascular health, particularly in epidemiological studies. It is clear from Table 1 that several
intervention studies, crossover studies, cross-sectional studies and randomised controlled trials (RCT)
indicate that dairy consumption may be cardioprotective due to lower levels of inflammatory markers
including TNF-α, IL-6, IL-13, MCP-1 and VCAM-1. Table 1 indicates that dairy products are associated
with a neutral or positive effect on inflammatory markers in both healthy and diseased individuals in
various forms of human trials. However, the mechanisms underlying the observed inverse associations
between the intake of specific dairy products and inflammation remain elusive. Some mechanisms
have been suggested for specific fatty acids such as CLA and various bioactive proteins [4,153].
As highlighted in Table 1, many studies that have evaluated the effects of dairy product consumption
on inflammatory markers tend to focus on low-fat dairy products, a point that has been previously
highlighted by Lordan and Zabetakis [4]. The study of only low-fat dairy product consumption may
have several limitations because of the reduced intake of the anti-inflammatory lipids of dairy products.
Therefore, the observed neutral effects of dairy product intake on inflammatory markers in Table 1,
may be due to the assessment of only low-fat dairy products in some studies. The prominent focus on
the study of low-fat dairy may be due to the negative perceptions associated with full-fat dairy products
in society, thus low-fat dairy products may be consumed more in the populations assessed. In addition,
there are also indications that the observed effects of dairy intake on inflammatory markers may be
dose dependent [154]. Notably in Table 1, fermented dairy products tend to reduce inflammatory
markers more than non-fermented products, which mechanistically may explain the observed greater
health benefits of fermented dairy consumption versus non-fermented dairy products. Further studies
are required to assess the effects of dairy product consumption and dairy lipid constituents on
inflammatory markers and cardiovascular health [4].
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Table 1. Summary of the findings of observational studies investigating the consumption of dairy products and their derivatives on inflammatory markers related to
cardiovascular diseases, obesity and metabolic syndrome in healthy and diseased individuals.
Author, Year Country Study Design Study Focus Outcome Conclusion
Thompson, 2005 [155] USA Dietaryintervention
The effects of high-dairy and high-fibre consumption
on weight loss in 90 obese subjects was assessed
CRP was reduced by 0.8 mg/L from baseline (p < 0.0001),
however there was no significant difference between the
dairy diet and the others tested
An insignificant reduction of CRP was
observed following dairy consumption in
obese participants
Sofi, 2010 [156] Italy Dietaryintervention
Effect of pecorino cheese naturally enriched with cis-9,
trans-11 CLA on inflammatory markers in 10 healthy
participants
Reduction in arachidonic acid-induced platelet aggregation
(pre: 87.8 ± 1.76% vs. post: 77.7 ± 3.56%; p = 0.04),
improvement of erythrocyte filtration rate and a reduction
of TNF-α (40.1%), IL-6 (43.2%) and IL-8 (36.5%)
Dietary short-term intake of pecorino cheese
rich in cis-9, trans-11 CLA caused favourable
biochemical changes of inflammatory and
atherosclerotic markers
Rosado, 2011 [157] Mexico Dietaryintervention
Effect of adding low-fat milk on anthropometrics,
body composition, CRP etc. in energy restricted diets
in 139 women
Change in CRP after low-fat milk was 0.2 mg/L
(95% CI 1.1–1.6)
Dairy intake had no significant effect on
CRP concentrations
Stancliffe, 2011 [154] USA Dietaryintervention
Effects of an adequate full-fat dairy diet versus
low-dairy (both mainly milk and yoghurt) intake on
inflammatory markers in 40 overweight individuals
with metabolic syndrome over a 12-week period
versus a low-fat control
After 7 days, the adequate full-fat dairy diet decreased
plasma malondialdehyde and oxidised LDL (35% and 11%
respectively, p < 0.01), TNF-α decreased by 35% (p < 0.05),
which further decreased by week 12. By week 12, decreases
in IL-6 (21%, p < 0.02) and MCP-1 (24%, p < 0.05) were
observed. Low-dairy intake exerted no effects on oxidative
or inflammatory markers
An increase in dairy intake attenuates
oxidative and inflammatory stress in
metabolic syndrome
Nestel, 2012 [158] Australia Dietaryintervention
Assessing the effects of low-fat or fermented dairy
product intake on inflammation and atherogenesis on
13 overweight participants, using 5-single meal tests
No significant changes in the levels of inflammatory
biomarkers (CRP, IL-6, IL-13, TNF-α, VCAM-1 and others)
were observed
Authors could not confirm the reported
increments in inflammation after high
fat meals
Esmaillzadeh, 2010 [159] Iran Cross-sectional Assessing the effect of dairy products oninflammatory markers in 486 women
Low-fat dairy was inversely associated with CRP (β =
−0.04), IL-6 (β = −0.02) and VCAM-1 (β = −0.06); high fat
dairy was positively associated with log-transformed
values of serum amyloid A (β = 0.08) and VCAM-1
(β = 0.05)
Evidence suggests there is an independent
relationship between dairy consumption and
some markers of inflammation and
endothelial dysfunction
Panagiotakis, 2010 [160] Greece Cross-sectional
The evaluation of effects of dairy product
consumption on levels of inflammatory markers in
blood samples from fasting adults with no evidence of
previous chronic inflammatory disease
Levels of inflammatory markers such as CRP, IL-6 and
TNF-αwere 29, 9 and 20% lower, respectively (p = 0.01),
in people who consumed more than 14 servings of dairy
per week compared with those who had fewer than 8
servings per week (p = 0.05)
This inverse association between dairy
consumption and levels of inflammatory
markers in healthy adults indicates that dairy
products may be protective against chronic
inflammatory diseases
Wang, 2011 [161] USA Cross-sectional
305 adolescents were tested for serum phospholipid
fatty acid markers of dairy intake (C15:0 & C17:0),
which were linked to biomarkers of inflammation by
generalised linear regression analyses adjusted for
age, gender, race, tanner score, total energy intake and
physical activity
Phospholipid dairy fatty acids, elevated by dairy
consumption, were inversely associated with CRP,
8-iso-PGF2α and urinary 15-keto-dihydro-PGF2α in
overweight but not in normal weight adolescents
(all pinteraction < 0.05). However, higher PL dairy fatty acid
levels were associated with lower IL-6 among all
adolescents. Adjustment for dietary intake of calcium,
vitamin D, protein, total flavonoids andω-3 fatty acids did
not alter the findings
Dairy-specific saturated fats C15:0 and
17:0 fatty acids, may contribute to the potential
health benefits of dairy products, especially for
overweight adolescents
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Table 1. Cont.
Author, Year Country Study Design Study Focus Outcome Conclusion
Gadotti, 2017 [162] Brazil Cross-sectional
To assess the effect of dairy consumption and plasma
inflammatory markers in 259 participants. Subjects
were assigned groups depending on inflammatory
status and multiple logistic regression tests were
conducted to estimate the odds ratio (OR) for the
inflammatory cluster across tertiles of dairy
consumption
The highest tertile of yoghurt consumption was 0.34
[95% CI: (0.14–0.81)] relative to the reference tertile,
demonstrating a linear effect (ptrend = 0.015). Cheese
consumption exhibited an OR of 2.49 (95% CI: (1.09–5.75))
relative to the reference
Increasing yoghurt consumption might have a
protective effect on inflammation, while
cheese consumption seems to be associated
with a pro-inflammatory status
van Meijl, 2010 [163] Netherlands Randomisedcrossover
Effects of low-fat milk and yoghurt intake on
inflammatory markers in 35 overweight or obese
participants versus carbohydrate controls for 8 weeks
No significant effects on IL-6, MCP-1, ICAM-1 or VCAM-1
versus control. TNF-α index decreased by 53 (p = 0.015)
Low-fat dairy consumption may increase
concentrations of s-TNFR but it has no effects
on other inflammatory markers of chronic
inflammation and endothelial function
Zemel, 2010 [164] USA Randomisedcrossover
Effects of a dairy-rich, high calcium diet on oxidative
and inflammatory stress in 10 overweight and 10
obese individuals compared with soy supplemented
eucaloric diets
After 7 days, dairy intake decreased oxidative stress by
lowering 8-isoprostane-F2α (12%, p < 0.0005), plasma
malondialdehyde (22%, p < 0.0005). Adiponectin increased
significantly (20%, p < 0.002). Inflammatory markers were
significantly reduced versus the control diet: IL-6 (13%,
p < 0.01); TNF-α (15%, p < 0.002); MCP-1 (10%, p < 0.0006)
An increase in dairy food intake produces
significant and substantial suppression of the
oxidative and inflammatory stress associated
with overweight and obesity
Nestel, 2013 [165] Australia Randomisedcrossover
Consumption of full-fat versus low-fat dairy on
biomarkers of inflammation in 12 overweigh
individuals
75% of those who consumed low-fat products versus
full-fat fermented products tended to have higher levels of
inflammatory markers tested (CRP, IL-13, TNF-α, VCAM-1
and others; ptrend < 0.001)
Short-term diets of low-fat dairy products did
not lead to a favourable biomarker profile
associated with CVD risk compared with the
full-fat dairy products. Full-fat fermented
dairy products are more favourable
Labonté, 2014 [166] Canada Randomisedcrossover
Assessing the impact of dairy intake versus energy
equivalent products on inflammatory markers in
112 healthy participants with systemic inflammation
After dairy consumption, no significant changes in CRP
(7.3%, p = 0.47). However, both the control and dairy diet
reduced IL-6 (17.6% and 19.9%, respectively; p < 0.0001 for
both, p = 0.77 for between-diet comparison
Short-term consumption of a combination of
low- and high-fat dairy products as part of a
healthy diet has no adverse effects on
inflammation
Dugan, 2016 [167] USA Randomisedcrossover
Effect of low-fat dairy consumption on hepatic
enzymes and inflammation in 37 participants with
metabolic syndrome versus a carbohydrate control
Lower levels of TNF-α (p = 0.028) and MCP-1 (p = 0.001)
were observed in women after low-fat dairy intake versus
the control group. The hepatic steatosis index was also
reduced (p = 0.001)
Three servings of dairy per day improved both
liver function and systemic inflammation in
subjects with metabolic syndrome
Zemel, 2008 [168] USA
Randomised
controlled
longitudinal
Evaluation of feeding calcium rich high-dairy
eucaloric diet and hypocaloric diet versus low dairy
group intake in obese participants over 24 weeks
High-dairy eucaloric diet and a hypocaloric diet resulted in
an 11% (p < 0.03) and 29% (p < 0.01) decrease in CRP,
respectively (post-test vs. pre-test), whereas there was no
significant change in the low-dairy groups. Adiponectin
decreased by 8% in subjects fed the eucaloric high-dairy
diet (p = 0.003) and 18% for the hypocaloric high-dairy diet
(p = 0.05)
Dietary calcium suppresses adipose tissue
oxidative and inflammatory stress
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Author, Year Country Study Design Study Focus Outcome Conclusion
de Aguilar-Nascimento,
2011 [169] Brazil
Randomised
controlled
longitudinal
Effects of an early enteral formula on the levels of
glutathione and inflammatory markers in 25 aged
patients with acute ischemic stroke. Group 1
consumed whey, group 2, the control
consumed casein
Mortality was similar between groups (33%; p = 1.00) and
was associated with higher IL-6 levels (group 1: 73.7 ± 24.7;
versus group 2: 16.6 ± 2.4 pg/dL; p = 0.04) and CRP
(82.0 ± 35.6 vs. 48.3 ± 14.5 mg/L; p = 0.02). Serum IL-6 was
lower (p = 0.03) and glutathione was higher (p = 0.03) in
whey protein-fed patients versus the casein group
Enteral formula containing whey protein may
decrease inflammation and increase
antioxidant defences in elderly patients with
ischemic stroke
Jones, 2013 [170] Canada
Randomised
controlled
longitudinal
Assessing a diet rich in calcium and dairy products on
weight loss and appetite during energy restriction in
49 overweight and obese individuals for 12 weeks,
versus a suitable control. A meal tolerance test was
carried out in week 12
MCP-1 was reduced after 30 mins with Dairy/Calcium
group compared with the control in the meal tolerance test
(p = 0.04). No change was observed for IL-6, TNF-α,
or IL-1β
Modest reduction in MCP-1
Pei, 2017 [171] USA Randomisedcontrolled
Premenopausal women (BMI 18.5–27 and
30–40 kg/m2) were randomised to consume 339 g of
low-fat yoghurt (yoghurt non-obese (YN); yoghurt
obese (YO)) or 324 g of soya pudding (control
non-obese; control obese (CO)) daily for 9 weeks
(n 30/group). Fasting blood samples were analysed
for various inflammatory markers
After 9-week yoghurt consumption, YO and YN had
decreased TNF-α/sTNFR RII. Yoghurt consumption
increased plasma IgM EndoCAb regardless of obesity
status. sCD14 was not affected by diet but LBP/sCD14
was lowered in both YN and YO. Yoghurt intervention
increased plasma 2-arachidonoylglycerol in YO but not
YN. YO peripheral blood mononuclear cells expression of
NF-κB inhibitor α and transforming growth factor β1
increased relative to CO at 9 weeks
Consumption of low-fat yoghurt for 9 weeks
reduced biomarkers of chronic inflammation
and endotoxin exposure in premenopausal
women compared with a non-dairy
control food
Wannamethee,
2018 [172] UK
Prospective
cohort study
This study investigated serum CLA (measured as a
% of total fatty acids) and the risk of incident heart
failure in 3806 older men aged between 60 and
79 years using metabolomics. The men were without
prevalent HF and were followed up for an average of
13 years, during which there were 295 incident
HF cases
CLA was adversely associated with cholesterol levels but
was inversely associated with CRP and NT-proBNP.
No association between CLA and CHD. High CLA was
associated with reduced risk of HF (hazard ratio [95%
confidence interval], 0.64 [0.43–0.96]; quartile 4 versus
quartile 1). Elevated CLA was associated with reduced
HF risk only in those with higher dairy fat intake, a major
dietary source of CLA (p = 0.03)
The reduced risk of HF was partially
explained by NT-proBNP. High dairy fat
intake was not associated with incident
coronary heart disease but was associated
with reduced risk of HF, largely because of
the inverse effect of CLA
BMI = body mass index; CHD = coronary heart disease; CI = confidence interval; CLA = conjugated linoleic acid; CRP = C-reactive protein; EndoCab = endogenous endotoxin-core
antibody; HF = heart failure; IL-X = interleukin-β/6/13 etc.; MCP-1 = monocyte chemoattractant protein-1; NF-κB = nuclear factor-κB; NT-proBNP = N-terminal prohormone of brain
natriuretic peptide; s-CD14 = soluble cluster of differentiation 14; s-TNFR = soluble tumour necrosis factor receptors; TNF-α = tumour necrosis factor-α; VCAM-1 = vascular cell
adhesion molecule-1.
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6. Trans Fatty Acids
Trans-fatty acids (TFA) have previously been associated with an increased risk of CVD [173].
TFA affect many CVD risk factors by increasing: LDL; lipoprotein(a); serum triglycerides; LDL particle
number; shifting LDL subclasses to more atherogenic small dense LDL; increasing inflammation;
and reducing HDL levels [174–176]. Thus, many dietary guidelines recommend limiting dietary TFA
intake to less than 1% of energy intake [28,177,178] and some countries such as Austria, Hungary,
Iceland, Latvia, Norway and Denmark have introduced legal bans that limit the percentage of artificial
TFA in oils and fats. In Denmark that limit is just 2% (2 g per 100 g) [179]. Other countries including
Lithuania and Sweden are close to adopting similar legislation. Dietary intake of TFA is characterised
by both industrial-TFA and ruminant TFA. In the margarine and cooking oil industries, during the
process of fat hardening, partial hydrogenation or deodorisation of vegetable oils can lead to the
production of artificial industrial TFA. In processed fats, elaidic acids (C18:1t9) are the most prominent
TFA, followed by trans-vaccenic acid [180,181]. In dairy products and ruminant fat, some trans-isomers
are produced naturally in small quantities by microorganisms in the rumen of ruminant animals, which
occurs due to the partial hydrogenation of cis-fatty acids, primarily linoleic acid and α-linolenic acid.
The most abundant TFA is trans-vaccenic acid (C18:1t11) [180,182]. Other biologically important TFA
include conjugated linoleic acids (CLA) such as rumenic acid (C18:2c9t11) and (C18:2t10,c12), which
are associated with a number of health benefits [4]. Notably except for CLA, all TFA in industrially
produced fat are also found in ruminant fat but the amounts of the individual TFA differ significantly
strongly between both types of fat [180].
Dietary intake industrial TFA increased after a surge in the production of industrial fats between
the 1960s and 1980s, in response to public health recommendations to ironically replace animal
products and tropical oils, both high in SFA [183]. However, as research advances generalising
fatty acids by the degree of unsaturation or the configuration of double bonds alone is unlikely to
predict biological responses. Thus, emerging evidence suggests that TFA from ruminant sources only
may not be as detrimental to health as previously thought [173,184], in fact some may even have
cardioprotective effects [176]. Ruminant trans-fatty acids constitute a typically 2–5% of the fat in dairy
products [185]. Generally, ruminant TFA accounts for 2–9% of fatty acid intake [186]. In addition,
the TRANSFAIR Study estimates that as much as half of all trans-fats consumed are ruminant TFA in
specialty diets, such as the Mediterranean diet [187], which is associated with positive cardiovascular
health benefits [188]. A study was conducted feeding either industrial TFA or ruminant TFA to LDL
receptor deficient mice (LDLr−/−); mice fed a diet of cholesterol supplemented with industrial TFA
(elaidic acid) stimulated atherosclerosis and plaque formation, whereas plaque formation was reduced
in mice that were fed the same cholesterol rich diet but consumed butter rich in vaccenic TFA (18:1t11)
instead of industrial TFA [186]. This may indicate a protective effect for ruminant vaccenic TFA against
atherosclerosis. A case control study in Costa Rica found that an adequate concentration of c9,t11-CLA
in adipose tissue was associated with a lower risk of myocardial infarction (MI; highest versus lowest
quintile; OR = 0.51; 95% CI = 0.36–0.71; p < 0.0001) and that dairy intake was not associated with risk of
MI, despite a strong risk associated with saturated fat intake [189]. A meta-analysis of cohort studies
found no association between ruminant TFA intake and CVD risk (RR, 0.92 (95% CI, 0.76–1.11); p = 0.36),
however suggested further research for confirmation. Further studies indicate that c9, t11-CLA exhibit
potent anti-inflammatory effects against IL-6 and TNF-α expression, as well as adiponectin secretion
in 3T3-L1 adipocytes [190,191]. A recent study has also shown that high dairy fat intake was not
associated with incident coronary heart disease but was associated with reduced risk of HF, largely
because of the inverse effect of the presence of serum CLA (measured as a % of total fatty acids), which
is elaborated further in Table 1 [172]. Furthermore, as reviewed by Lordan and Zabetakis [4], CLA
enriched dairy products has a neutral or positive effect on circulating inflammatory markers and lipid
profiles of healthy and diseased participants.
There is also evidence to suggest that circulating trans-palmitoleic acid (C16:1t9), which occurs in
both dairy fat and partially hydrogenated oils, is associated with lower atherogenic dyslipidaemia,
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insulin resistance and the incident of diabetes, which may explain previously observed metabolic
benefits of dairy consumption [192]. However, controversy remains, thus more research is required
to differentiate between artificial and ruminant TFA on CVD risk factors [193]. It is clear that TFA of
industrial origin are associated with an increased risk of CVD. Putative evidence suggests that TFA of
ruminant origin may be associated with beneficial effects against CVD, however further research with
a focus on dairy products is required to confirm these observations.
7. Fermented Dairy Products and Cardiovascular Health
Fermented milk beverage consumption is on the rise due to consumers’ perception of its healthy
effects, widely disseminated by increasing numbers of studies describing the importance of the
different nutrients and bioactive compounds [194]. Fermented dairy products include various yoghurts,
cheeses and fermented milk products such as kefir. Fermented dairy products are synonymous
with the delivery of probiotics, which are a microorganisms that are alive when they arrive to the
gut and have the potential for therapeutic and preventative health benefits upon consumption by
improving host intestinal microbiota [195]. Fermented dairy products tend to possess more health
benefits than fluid milk upon consumption [148]. Increased consumption of fermented dairy foods
is associated with reduced LDL cholesterol [10], reduced hypertension risk [123] and CVD risk [17],
there is also a suggestion that there may be a dose response [196]. Although these patterns are
observed in several studies (Table 1), dairy food intake is associated with many confounders that are
generally associated with better health outcomes such higher educational levels and socioeconomic
status [31,197]. Furthermore, children who consume >60 g of yoghurt a day have a higher overall
diet quality, nutrient intake, lower pulse pressure (4–10 years old) and lower HbA1c concentrations
(11–18 years old) indicating favourable cardiometabolic health [198].
A recent study comparing fermented and non-fermented dairy products with all-cause mortality
in a Swedish cohort found that there was a 32% increased hazard (HR: 1.32; 95% CI: 1.18–1.48) in
high consumers of non-fermented milk (≥2.5 times/day), when compared to consumers of milk
(≤1 time/week), Whereas butter was 11% (HR: 1.11; 95% CI: 1.07–1.21). All non-fermented milk-fat
types were independently associated with increased HRs but were lower in consumers of medium and
low-fat milk, when compared with full-fat milk. Fermented milk intake (HR: 0.90; 95% CI: 0.86–0.94)
and cheese intake (HR: 0.93; 95% CI: 0.91–0.96) were negatively associated with mortality [199].
Meta-analyses have shown that fermented dairy products can have an inverse association with
T2DM [132,136] and cheese consumption was not associated with an increased risk of all-cause
mortality [12,200]. In a crossover-controlled study, yoghurt consumption has also been shown to
increase HDL levels in 29 hypocholesterolaemic women The HDL concentration increased significantly
by 0.3 mmol/L (p = 0.002). The ratio of LDL/HDL cholesterol desirably decreased from 3.24 to 2.48
(p = 0.001) [201]. A recent meta-analysis supports the observed associations that fermented dairy
product consumption had a positive or neutral effect on CVD risk [102]. In particular, fermented
dairy intake was associated with a reduced risk of stroke and T2DM. Other studies have found that
fermented dairy products have mostly positive or neutral effects on fasting plasma glucose levels [202],
however one study has shown that fermented milk lowers fasting plasma glucose levels in patients
with T2DM [203].
As current dietary guidelines generally place an emphasis on the reduction of SFA intake, it would
be expected that cheese consumption would be associated with an increased risk of CVD. Cheese
provides a high intake of SFA and cholesterol and is also a major source of calcium and protein [204].
Epidemiological evidence indicates that cheese consumption may be less atherogenic than previously
assumed. Observational studies have failed to identify a significant association between high cheese
or dairy fat intake and coronary heart disease [205–207]. Cheese consumption has been associated
with a significantly reduced risk of stroke and CHD [208]. Similar effects have been observed in
yoghurts, which are a diverse complex nutrient-rich matrix that have been associated with lower
incident risk of CVD [209], diabetes [20] and metabolic syndrome, particularly when consumed with
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fruit [144,210]. Mechanistically these effects may be due to the presence of bioactive lipids and peptides
with anti-inflammatory properties [4], and/or the observed effects of high calcium intake from cheese,
which may lower SFA intake, reducing the risk of high cholesterol levels.
Several epidemiological studies have found that populations that traditionally consume high
amounts of fat have low incidences of CVD and mortality, which was first defined as the French
paradox by Renaud and De Lorgeril [211]. It is thought that high consumption of cheese and wine in
the French diet may be responsible for these effects. In particular, bioactive molecules in dairy products
can stimulate intestinal alkaline phosphatase, a potent endogenous anti-inflammatory enzyme [212].
It is thought that bioactive lipids and peptides and biomolecules from the cheese moulds may be a
number of cardioprotective properties, including angiotensin-I converting enzyme (ACE) inhibitors
and molecules regulating haemorheological functions, blood coagulation and blood pressure [212].
In particular, cheeses that are moulded such as Camembert and Gorgonzola may have positive effects
for cardiovascular health; especially Roquefort, which is a blue cheese is particularly cardioprotective
due to the presence of bioactive molecules such as andrastins A–D and roquefortine [213]. Fermented
dairy products may also induce their cardioprotective effects due to the intake of bacterial metabolites
and probiotics. Probiotics arrive to the gastrointestinal tract alive, where they can exert their effects
directly. Probiotic intake due to supplementation or consumption of fermented dairy products has
been associated with potential cardiovascular health benefits, including positive effects on blood
pressure and hyperlipidaemia and they may exert anti-inflammatory activities [214]. The mechanistic
explanations surrounding the positive effects of fermented dairy product consumption remain elusive.
Further studies may help to elucidate the intriguing cardioprotective effects of moulded cheeses that
may help to elucidate the mechanisms that are responsible for the French paradox.
Fermented dairy products are an excellent source of vitamin K. Vitamin K is essential to blood
clotting and coagulation as it is an enzyme cofactor for γ-carboxylation of peptide-bound glutamate
residues [215]. However, vitamin K is also involved in the regulation of bone and soft tissue
calcification, cell growth and proliferation, cognition, inflammation and oxidative processes [216].
In particular, fermented dairy products contain menaquinones—also known as vitamin K2—a
collection of isoprenologues mostly originating form bacterial synthesis [217]. Vitamin K2 includes a
range of vitamin K isoforms that differ structurally from vitamin K1 also known as phylloquinones,
which are mainly found in leafy green vegetables. Vitamin K2 is the most biologically active form
of vitamin K and it has a longer half-life than vitamin K1 [36,218,219]. A growing body of evidence
suggests that vitamin K has beneficial effects on cardiovascular health [220–223]. Observational studies
have demonstrated that low vitamin K status plays a potential role in CVD development, particularly
in high-risk populations and individuals suffering chronic kidney diseases [36,224]. In comparison to
other foods, fermented dairy and other animal products have a high content of vitamin K2. Fermented
dairy products, in particular cheese, yoghurt and kefir contain vitamin K2 [219,225], thus consumption
of fermented dairy products may be beneficial for human cardiovascular health. Randomised trials
have provided some evidence to support the beneficial effects of vitamin K2 on bone health and some
intervention trials that assessed vitamin K in conjunction with vitamin D have demonstrated positive
results on cardiovascular-related outcomes [36]. However, randomised trials have not yet examined
vitamin K2 intake in relation to cardiovascular outcomes [36,217].
In summary, fermented dairy products have positive effects on cardiovascular health (Figure 1)
and may be even more beneficial than non-fermented dairy products. However, none of the putative
bioactive compounds in dairy foods such as proteins, lipids, phospholipids, vitamin D, vitamin K,
or probiotic bacteria has consistently explained the benefits of dairy intake on cardiovascular health.
The process of fermentation leads to the structural change of lipids and proteins in cheese and
yoghurt, which may be responsible for some of the observed effects [4,226]. Several bioactive
peptides and phospholipids present in fermented dairy products have protective effects, including
the anti-inflammatory effects of phospholipids and the antioxidant properties of plasmalogens.
The structure of lipids and phospholipids in the milk fat globule membrane (MFGM) may also
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play a role in modulating plasma cholesterol levels, further supporting the evidence surrounding the
food-matrix effect [226,227]. How these different constituents and properties influence cardiovascular
risk factors is poorly understood. Mechanistic studies are key to identifying the missing links that
explain the positive cardiovascular health benefits of consuming fermented dairy products.
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8. Functional Alternative Dairy Foods and Consumer Trends
Increasing interest in the relationship between diet, health and well-being is likely to drive a
growth in demand for products that have positive impacts on health. Consumer research indicates, that
the functional food markets are growing worldwide and that there is a greater demand for functional
foods against specific diseases [120]. Dairy products lead the charge in this field in terms of the
creation of dairy products low in fat, or containing probiotics, bioactive peptides, altered lipid profiles,
cholesterol lowering capabilities and vitamin, protein and mineral fortification [228–230].
8.1. Cholesterol-Lowering Dairy products
Several food producers have taken it upon themselves to introduce dairy products to the market
that target hypercholesterolemia, which is caused by high SFA intake. Phytosterols and their saturated
form phytostanols are a group of steroid alcohols naturally present in fruits, legumes, nuts, seeds,
vegetables and vegetable oils [231,232]. These molecules have many applications and are generally
found as food additives or ingredients in ‘cholesterol-lowering’ dairy products. The inclusion
of stanols/sterols as an ingredient in foods is recognised as safe by the European Food Safety
Authority [233]. The function of plant stanol esters is to partly block cholesterol absorption in the
digestive tract and thereby reduce total cholesterol and LDL cholesterol levels. Structurally, they are
similar to cholesterol but their absorption rate is much lower. Foods with added plant stanol esters may
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provide the consumer an opportunity for cardiovascular disease prevention [230,234]. As consumer
awareness increased, the number of products containing plant sterols or plant stanols and their esters
has increased. In addition, milk-based beverages containing phytosterols have gained a distinct place
among these type of functional foods, as phytosterols do not readily dissolve in water based products
and so low-fat versions are not as common [235]. Some studies have seen a benefit for the consumption
of phytosterols to lower serum cholesterol levels. One study showed that the consumption of 1.7 g/day
of phytosterols by hypercholesterolaemic men had a lowering effect on serum cholesterol levels [236].
Another study found daily consumption of low-fat milk containing 1.6 g phytosterols was effective in
reducing LDL levels by 8% after 6 weeks in 194 hypercholesterolaemic individuals [237]. In a recent
randomised double-blind crossover, placebo-controlled study in moderately hypercholesterolaemic
subjects (n = 40) aged between 20 and 50 years old, who consumed a yoghurt drink with 4 g of plant
stanol esters (Benecol®) compared to a normal yoghurt drink caused a statistically significant decrease
in total cholesterol and low density lipoprotein cholesterol by 7.2% and 10.3% [230]. Similar products
to Benecol® exist on the market such as Flora ProActiv yoghurt drink, which claims to be ‘clinically
proven to reduce cholesterol’ [233]. Although studies show that these products may lower serum
cholesterol levels and thus possibly lower cardiovascular risk, as previously discussed, lowering serum
cholesterol levels alone is not enough to prevent CVD development. Therefore, long term studies are
required to assess the effects of long term consumption of phytosterols on cardiovascular health.
8.2. Plant Based Milk Alternatives
Plant-based alternatives to dairy products have been produced to satisfy consumer needs and to
accommodate an increased uptake of vegan, ‘clean eating’ lifestyles and lactose intolerance. In fact,
in many countries fluid milk consumption has decreased, whereas the consumption of plant-based
alternatives is on the rise. Almond milk has surpassed soy milk as the main alternative beverage
consumed in the United States. Plant milk substitutes are suspensions of dissolved and disintegrated
plant material, resembling cow’s milk in appearance [238]. These ‘milk’ products include soy, almond,
rice, coconut, flax or hemps milk. Each product is identified as a satisfying alternative for consumers
who desire a milk-like consistency for cereal or other food combinations [239]. These products are
generally perceived as “healthier” by consumers and each product is marketed to promote a different
health benefit, as consumers are trending away from animal-based products over concerns about
lactose, fat and cholesterol [239]. The nutritional properties of these products are highly variable and
depend on the plant source, processing and fortification. However, these products are not nutritionally
similar to dairy products, often inferior and as such they are not considered a part of the dairy food
group in nutritional guidelines [27,240].
Some products have extremely low calcium and protein contents and so consumer awareness
is imperative, when considering the use of plant-based substitutes for cow’s milk in the diet [240].
Many of these beverages also contain high amounts of sugar, which may have consequences to
frequent consumers [240]. In general, little research has been done to assess the health benefits of these
products, however as soy milk has been popular for over 25 years more research exists. Although not
completely established, it is thought that soy protein may have hypocholesterolaemic effects [241],
reduce blood pressure [242] and various other risk factors, however the data remains inconsistent [243].
Some studies indicate that soy products may possess anti-inflammatory properties, however a recent
study on mice has shown that bovine milk possessed anti-inflammatory properties, whereas soy bean
was pro-inflammatory in an mouse model of obesity [244]. In addition, it is not yet known what effect
long-term consumption of plant-based alternatives will have on cardiometabolic health. It is generally
assumed that as they are plant-based products they will have a positive impact on cardiovascular health.
However, apart from soy products, there is a distinct lack of research and epidemiological evidence to
substantiate any health claims in relation to plant-based alternative beverages and their cardiometabolic
health effects. Therefore, plant-based beverages have not been accepted by everyone. In December
2016, producers of plant-based beverages were challenged by members of the United States Congress
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and the dairy industry; A request was made to the American Food and Drug Administration to demand
that producers refrains from using the words ‘milk’, ‘yoghurt’ or ‘cheese’ to describe their plant-based
products. Concerns were voiced about their nutritional quality and it was claimed that the producers
were misleading their customers [245]. A bill was introduced to the House of Representatives and was
referred to the Subcommittee on Health, which has yet to carry out any further action.
8.3. Alternatives to Bovine Milk: Caprine and Ovine Milk
Bovine milk is consumed globally and accounts for 85% of the total global milk production,
followed by buffalo (11%), goat (2.3%), sheep (1.4%) and camel milk (0.2%) [246]. Interestingly, despite
the dominance of bovine milk production, on a global basis, more people consume goat milk than
milk from any other single species [247]. This demand is also due to an increased trend of health
conscious consumers and an increased purchase of caprine dairy products due to allergy issues related
to bovine products [248]. The production of ovine and caprine dairy products is prominent in the
Mediterranean basin and the Middle East. Outside of these distinct regions, sheep and goat milk
products are considered a delicacy and their consumption is not common particularly in countries like
Ireland and the UK where consumption of these products is not widespread [148]. Neither caprine
or ovine dairy products have been extensively studied for their effect on cardiometabolic health,
despite their high levels of consumption in developing countries. The lipid fraction of caprine milk is
significantly different to bovine milk and is a much-overlooked component. First of all, the lipid in
both caprine and ovine milk is present in fat globules, which in ovine products are less than 3.5 µM,
among ruminants sheep milk fat globules are the smallest [249]. This is advantageous as both caprine
and ovine milk have increased digestibility, thus the milk lipid is metabolised more efficiently in
humans. This may be beneficial for the uptake of bioactive lipids present in the milk fat of caprine and
ovine milk products [4,148].
Caprine milk exceeds bovine milk in MUFA, PUFA and medium chain triglycerides (C6–C10,
length of the carbon chain), which all are known to be beneficial for human health, especially for
cardiovascular conditions [250]. Caprine milk is also high in vitamins A, B1 and B12 as well as
calcium and phosphorus content when compared to bovine and ovine milk [249]. Caprine milk
fat content is approximately 3.8%, ovine milk fat is 7.9%, whereas bovine milk is approximately
3.6% [251]. Both caprine and ovine milk contain bioactive lipids such as CLA, which account for
2–4%, of total fatty acids esterified in phospholipids [252]. These lipids are associated with a number
of anti-inflammatory properties that may have positive effects on cardiovascular health [4] Studies
using ovine cheese have established that there is a reduction of inflammatory markers, platelet
aggregation [156], modulation of plasma lipid profiles and a reduction of endocannabinoid biosynthesis
upon ovine cheese consumption [253]. Similarly, caprine milk, yoghurt and cheese has the potential to
reduce platelet aggregation in humans [150,152]. It is also suggested that the polar lipid (phospholipid
and sphingolipid) content of caprine and ovine dairy products may be responsible for some of the
antithrombotic effects observed [4,53].
Ovine milk and dairy products have been associated with positive effects on cardiovascular
health [148]. The world’s largest producer of sheep milk is China (12.2%) and the leading producer
in Europe is Greece (8.7%), followed by Romania (7.2%) and Italy (6.1%) [254], in stark contrast to
Ireland where ovine dairy farms are rare. Sheep’s milk is mainly used for the production of fine
cheese varieties, yoghurt and whey cheeses [255]. The high levels of protein, fat and calcium by casein
unit make it an excellent matrix for cheese production [256]. The nutritional value of sheep milk
is higher than that of either bovine or caprine milk, with higher levels of proteins, lipids, minerals
and vitamins essential to human health [246,254]. Ovine milk is high in caproic, caprylic and capric
acid. The most predominant fatty acids in sheep milk and yoghurt are oleic acid (C18:1n9), followed
by palmitic acid (C16:0) and myristic acid (C14:0), respectively [246]. Human diets high in oleic
acid are reported to decrease the level of LDL cholesterol, whereas HDL cholesterol levels are not
significantly affected [148,257]. A recent study has shown that yoghurt intake, from either ewe’s or
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cow’s milk, at levels of consumption compatible with a varied diet, neither decreases nor increases
plasma lipoprotein cholesterol levels in apparently healthy individuals [194]. These neutral effects
on serum cholesterol levels and the positive anti-inflammatory and antithrombotic effects that have
been observed in humans indicate that ovine dairy products, in particular their lipid fraction may
be cardioprotective upon consumption. In addition to their bioactive lipid fraction, dairy products
derived from ovine milk have angiotensin-converting enzyme (ACE) inhibitor peptides that also have
positive effects on cardiovascular health [258,259]. Therefore, fermented caprine and ovine dairy
products may possess potent cardiovascular health effects that warrant further investigation.
8.4. Functional Foods—Kefir
Consumer trends for functional foods has led to the increase of various yoghurt drinks on
the market. However, kefir milk has gained considerable attention for its putative health benefits.
When milk is inoculated with kefir grains they produce acidified fermented milk that is slightly
carbonated and contains a small amount of alcohol. The aforementioned kefir grains are microbially
derived protein and polysaccharide matrices that contain a community of bacterial and fungal
species that are essential to kefir fermentation [260]. When fermenting, lactic acid, bioactive peptides,
exopolysaccharides, antibiotics and bacteriocins are produced [225,261] and the fatty acid composition
is altered [262]. The microorganisms in kefir have probiotic potential and may have a positive impact
on gut health. However, the microbial composition of kefir is highly diverse and it is not known
what health benefits can be attributed to the actions of specific microbes that are present in the
matrix [263]. Kefir has been associated with a number of positive effects on blood lipid profiles in
animal models [264,265] which has been reviewed in great detail by Rosa et al. [225]. However, in
mildly hypercholesterolaemic men who consumed kefir as part of their diet for 4 weeks there was
no significant change to total serum cholesterol, LDL cholesterol, HDL cholesterol, or triglyceride
concentrations [266]. Another study examined the effect of kefir on the glucose and lipid profile in
patients with T2DM. They demonstrated that Kefir milk decreased fasting glucose and HbA1C levels
and can be useful in the prevention of T2DM [267]. Other animal models have also demonstrated that
kefir milk may possess a number of anti-inflammatory properties [225] but these effects have yet to
be demonstrated in humans. Although discrepancies may exist between animal and human studies,
it may be in large part due to the fact that different kefir grains were used for each of these studies and
the study timeline were different [263]. It seems that kefir milk is highly unexplored and although there
are a resounding number of studies that claim various health benefits, it remains to be seen what effect
kefir milk has on human cardiovascular health.
9. Conclusion: Dairy Fats and Cardiovascular Diseases, Do We Really Need to Be Concerned?
The role that dairy products play in human health has been contested for decades. Generally
the literature agrees that dairy products are neutral or beneficial to human health as evidenced
by several meta-analyses and randomised, controlled trials [4]. However, do we really need to be
concerned about whole fat dairy product consumption? Or should dietary recommendations continue
to support the consumption of low-fat or non-fat dairy products, while limiting the intake of full-fat
milk and dairy? Previous research indicated that reducing serum cholesterol levels would lower
cardiovascular risk, however, CVD are a multifaceted disease, which requires a multifaceted approach
to primary prevention. It is clear the reductionist approach to dietary research and the formation of
dietary guidelines is obsolete in the face of new evidence suggesting that systemic inflammation is
the key underlying biochemical phenomenon at the centre of atherosclerosis and the onset of major
cardiovascular events [4,53].
Apart from genetic and environmental influences, maladaptive diet and lifestyle are central to
the development of CVD and are a key modifiable risk factor for its prevention [53]. Despite the
previous concerns about dairy product consumption due to the SFA content, it has been shown that
not all SFA are created equal and that the presence of specific fatty acids (C14:0,C15:0, C17:0, CLA
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and trans-palmitoleic) in circulation are associated with a lower incidence of several cardiometabolic
diseases, however some may simply be markers of dairy intake [268]. Subsequent research indicates
that the dairy food matrix also plays a major role in nutritional research. Consequently, the predicted
health benefits of some foods based on their individual nutrient composition does not always
exhibit the predicted effect in clinical research. Further human studies may discern the mechanisms
surrounding fatty acids and their individual effects on cardiometabolic health.
Several meta-analyses point to the resounding conclusion that, although dairy products contain
a high SFA content, their consumption induces a positive or neutral effect on human cardiovascular
health [16,17,269]. In addition, consumption of full-fat dairy products contributes to higher intakes of
significant nutrients, in particular vitamin D and vitamin K. Considering current scientific evidence,
after years of controversy the negative image of milk fat is weakening. Therefore, consumers can
continue to moderately consume full-fat dairy products as part of a healthy and balanced lifestyle,
however fermented dairy products would be preferential for optimum nutrient intake and potential
cardiovascular health benefits. The authors suggest that less emphasis is needed on the impact of milk
and dairy product consumption on serum cholesterol levels but more emphasis should be placed on
inflammatory biomarkers to elucidate the cardioprotective mechanisms of dairy products.
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